@article{OehlerBrackBlumetal.2021,
  author    = {Oehler, Beatrice and Brack, Alexander and Blum, Robert and Rittner, Heike L.},
  title     = {Pain Control by Targeting Oxidized Phospholipids: Functions, Mechanisms, Perspectives},
  series = {Frontiers in Endocrinology},
  volume    = {11},
  journal   = {Frontiers in Endocrinology},
  issn      = {1664-2392},
  doi       = {10.3389/fendo.2020.613868},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-223432},
  year      = {2021},
  abstract  = {Within the lipidome oxidized phospholipids (OxPL) form a class of chemically highly reactive metabolites. OxPL are acutely produced in inflamed tissue and act as endogenous, proalgesic (pain-inducing) metabolites. They excite sensory, nociceptive neurons by activating transient receptor potential ion channels, specifically TRPA1 and TRPV1. Under inflammatory conditions, OxPL-mediated receptor potentials even potentiate the action potential firing rate of nociceptors. Targeting OxPL with D-4F, an apolipoprotein A-I mimetic peptide or antibodies like E06, specifically binding oxidized headgroups of phospholipids, can be used to control acute, inflammatory pain syndromes, at least in rodents. With a focus on proalgesic specificities of OxPL, this article discusses, how targeting defined substances of the epilipidome can contribute to mechanism-based therapies against primary and secondary chronic inflammatory or possibly also neuropathic pain.},
  language  = {en}
}
@article{UeceylerSommer2014,
  author    = {{\"U}{\c{c}}eyler, Nurcan and Sommer, Claudia},
  title     = {High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know},
  series = {Pain and Therapy},
  volume    = {3},
  journal   = {Pain and Therapy},
  number    = {2},
  issn      = {2193-651X},
  doi       = {10.1007/s40122-014-0027-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-120669},
  pages     = {73-84},
  year      = {2014},
  abstract  = {Neuropathic pain is a frequent and disabling condition with diverse underlying etiologies and is often difficult to treat. Systemic drug treatment is often limited in efficacy. Furthermore, adverse effects may be a limiting factor when trying to reach the necessary dose. Analgesics that can be applied topically have the potential to largely overcome this problem. They may be of particular advantage in localized neuropathic pain syndromes such as postherpetic neuralgia or small fiber neuropathy. Capsaicin, the pungent component of chili peppers, is a natural ligand of the transient receptor potential vanilloid 1 channel and has long been used as topically applicable cream with concentrations of 0.025 to 0.075\%. In 2009, a high-concentration transdermal capsaicin 8\% patch (Qutenza ; Acorda Therapeutics, Inc., Ardsley, NY, USA; Astellas Pharma Europe Ltd., Chertsey, Surrey, UK) was introduced for the treatment of peripheral neuropathic pain syndromes other than of diabetic origin in adults. It has since been widely used in diverse neuropathic pain disorders. In this review article, we summarize current knowledge on Qutenza, its advantages and problems, and expose unmet needs.},
  language  = {en}
}